Treatment Clinical Trials in Nanjing, Jiangsu
6 recruitingNanjing, Jiangsu, China
Showing 1–6 of 6 trials
Recruiting
Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
Stroke, IschemicStroke, AcuteEndovascular Treatment
Nanjing First Hospital, Nanjing Medical University300 enrolled1 locationNCT04230785
Recruiting
Early Phase 1
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
EfficacyTreatmentChronic Kidney Diseases+3 more
The First Affiliated Hospital with Nanjing Medical University9 enrolled1 locationNCT04592640
Recruiting
Early Phase 1
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
DC-CIK TreatmentRegorafenib
JIANG LONGWEI14 enrolled1 locationNCT07343791
Recruiting
Not Applicable
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
Follicular LymphomaTreatment Naive
The First Affiliated Hospital with Nanjing Medical University15 enrolled1 locationNCT07126678
Recruiting
Not Applicable
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
StrokeICAD - Intracranial Atherosclerotic DiseaseICAS - Intracranial Atherosclerosis+3 more
Beijing Tiantan Hospital792 enrolled18 locationsNCT04948749
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891